Professor Trevor Jones
Director-General of the Association of the British Pharmaceutical Industry
Professor Jones is Director General of the Association of the British Pharmaceutical Industry (ABPI), representing over 100 research-based prescription medicine companies to Government, the media and international agencies; including the UK, European Parliament and Commission. Prof Jones is a member of the UK Government : Pharmaceutical Industry Ministerial Strategy Group on Pharmaceuticals and is on the Board of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
He has served on a number of national and international Commissions. He was, for 12 years, a member of the Medicines Commission of the UK Government Medicines Control Agency.
Professor Jones is Deputy Chairman of Council and visiting professor at King’s College, University of London. He has been awarded honorary doctorates from the universities of Nottingham, Bath, Strathclyde, Bradford and Athens, and gold medals from the Comenius University and the Royal Pharmaceutical Society. He is a Fellow of a number of learned societies, including the Royal College of Physicians, the Royal Society of Chemistry, The Royal Pharmaceutical Society and King’s College London.
He was honoured by Her Majesty the Queen by the award of CBE in the 2003 New Year's Honours List.
He is Scientific Director and Chairman of the Scientific Advisory Board of the venture capital business, Merlin Biosciences, and Chairman of the stem cell biotech company, ReNeuron.
From 1987-94, he was a main board director of The Wellcome Foundation, where he was responsible for R&D, including the development of medicines such as AZT (for HIV AIDS), Zovirax (for Herpes infections), Lamictal (for Epilepsy), Malarone (for Malaria), Zomig (for Migraine), Exosurf (for infant respiratory distress syndrome),Wellferon (for hepatitis) plus an extensive range of OTC formulations.
In addition, Professor Jones’ responsibilities at Wellcome included its biotechnology activities and R&D into tropical medicines. The latter involved research with WHO and other agencies (e.g. Walter Reed) covering, inter alia, onchocerchiasis, shistosomiasis, leishmaniasis, trypanosomiasis, chagas disease and malaria. He was particularly involved in the development of a combination of atovaquone and proguanil (Malarone) to combat multidrug resistant plasmodium falciparum and is a founder of the Geneva-based, public: private partnership, Medicines for Malaria Venture (MMV).